ALK-Abelló og Schering-Plough indgår strategisk samarbejde om udvikling og kommercialisering af ALK-Abellós tabletbaserede allergivacciner mod græspollenallergi (GRAZAX®), husstøvmideallergi og ragweedallergi til det nordamerikanske marked.
Recommended Reading
-
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company’s president & CEO, Peter Halling, is scheduled to participate in a fireside chat at the Jefferies Global Healthcare...
Read More -
ALK will present phase II data from the ALLIANCE trial of its once-daily investigational sublingual immunotherapy (SLIT) tablet for peanut allergy1,2,3 at the American College of Allergy, Asthma &...
Read More